Modulight (MODU) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
21 Aug, 2026Executive summary
Completed patient recruitment for a key phase III clinical trial ahead of schedule, initiating a year-long follow-up period before FDA discussions.
R&D pipeline expanded to 36 projects, with strong progress and a growing share of large customers, especially in life science and semiconductor sectors.
Approved as a supplier to a major global semiconductor company, with increased activity among significant industry players and deliveries to quantum computing firms.
Strategy shift to focus on PPT business since 2022/2023 is yielding results, with triple-digit growth and increased customer interest.
Operational efficiency and cost savings contributed to positive EBITDA and reduced negative free cash flow.
Financial highlights
Q2 2026 revenue: EUR 1,604 thousand (down 18% YoY); H1 2026 revenue: EUR 3,099 thousand (down 13% YoY).
Q2 2026 EBITDA: EUR 37 thousand (2.3% margin, up 185% YoY); H1 2026 EBITDA: EUR 367 thousand (11.8% margin, up 29% YoY).
Q2 2026 EBIT: EUR -1,346 thousand; H1 2026 EBIT: EUR -2,410 thousand.
Q2 operating cash flow: EUR 22,000; H1 operating cash flow: EUR 841,000.
Cash and cash equivalents at period end: EUR 7,799 thousand; net debt: EUR -5,759 thousand.
Outlook and guidance
Revenue and EBITDA are expected to grow in 2026, with continued quarterly fluctuations anticipated.
Strategic objectives for 2026-2027 include strong annual growth, return to profitability, and achieving positive cash flow by period end.
Guidance aims to enhance transparency and predictability for investors, with updates in interim reports or upon material changes.
Strategy focuses on scaling the PPT model, expanding applications, and ramping up mass production.
Diversified customer base and increased project maturity support confidence in growth.
Latest events from Modulight
- EBITDA rose 157% to €330k as PPT and pipeline growth offset a 7% revenue decline.MODU
Q1 2026 - Record revenue growth and strong EBITDA, driven by PPT expansion and project pipeline.MODU
Q4 2025 - Revenue up 176% YoY, losses narrowing, and PPT business driving strong operational gains.MODU
Q3 2025 - Q2 revenue doubled and EBITDA neared zero as the pipeline and global customer base expanded.MODU
Q2 2025 - Q3 revenue up 58% YoY, EBITDA loss narrows, and PPT model and R&D pipeline expand.MODU
Q3 2024 - Q2 2024 revenue fell 13% YoY, but EBITDA loss narrowed and cash flow improved as the pipeline grew.MODU
Q2 2024 - Revenue up 52% and EBITDA up 56%, driven by US growth and pay-per-treatment expansion.MODU
Q1 2025 - Q4 revenue up 40% YoY, cash flow and margins improved as PPT model reached 50 hospitals.MODU
Q4 2024